Oramed Pharmaceuticals Inc., based in Jerusalem, is a leading pharmaceutical company that specializes in the development of oral delivery technology for drugs typically administered through injection. Established in 2006, Oramed has a team of experienced professionals with extensive expertise in the business and pharmaceutical industries, supported by world-class scientific experts. The company's groundbreaking technology has resulted in their flagship product, an oral insulin capsule.

This innovative solution has the potential to significantly improve the lives of millions of individuals worldwide, particularly type 2 diabetes patients who can now begin insulin therapy earlier without the fear of needles. Currently, Oramed's oral insulin is undergoing advanced Phase 3 clinical trials under the supervision of the US FDA and the European EMA. In addition to oral insulin, Oramed's proprietary POD™ technology has the potential to revolutionize the administration of various protein-based therapies that are currently only available through injection.

The company has successfully tested its technology through pre-clinical and clinical studies, showcasing the effectiveness of their orally ingestible insulin capsule, ORMD-0801, and their oral GLP-1 analog capsule, ORMD-0901. With its commitment to innovation and improving patient experiences, Oramed Pharmaceuticals is at the forefront of transforming drug delivery methods and enhancing healthcare outcomes